SLS Stock Faces Binary Setup: Maxim Group’s 92% Upside Call vs. Realistic Phase 2 Doubts

The immediate driver for SLS stock is a dual catalyst in its acute myeloid leukemia (AML) program. Shares jumped nearly 6% in overnight trading on Wednesday after the company flagged "potent" preclinical data for its AML drug SLS009 ahead of the AACR 2026 conference. CEO Angelos Stergiou called the findings "compelling," highlighting activity even in high-risk AML mutations like ASXL1 and TP53. This data, which shows the drug helps drive leukemia cells toward self-destruction, provides a tangible near-term event for the stock.

This news arrived just days after Sellas announced another key milestone: the enrollment of its first patient in a randomized Phase 2 trial for SLS009. The new study targets newly diagnosed AML patients unlikely to benefit from standard Venetoclax and Azacitidine therapy, a high-unmet-need group. The trial is designed to enroll around 80 patients across the U.S. and Europe, with topline data expected in the fourth quarter.

This sequence of events-potent preclinical data followed by Phase 2 enrollment-has fueled the stock's momentum. SLS has surged over 300% in the past year, with a 58.6% gain in the last month. The recent 6% pop on Wednesday is a direct reaction to the specific catalyst of the preclinical data being called "compelling" and set for presentation at a major conference. For an event-driven investor, this is the setup: a late-stage biotech with a promising pipeline advancing key clinical steps, creating a clear binary event (the AACR presentation) that could move the stock further.

The Analyst Thesis: Quantifying the "92% Upside"

The recent price target revision from Maxim Group analyst Jason McCarthy is the standout call. He raised his target to $10 from $7, citing the "compelling" preclinical data and Phase 2 enrollment as catalysts. That move implies an 85.87% increase from the stock's recent price around $5.38. This is a major upgrade from his own prior target and represents a bullish thesis that the company's recent momentum is just the beginning.

Yet this view is an outlier against the broader Wall Street consensus. The median price target from the four analysts tracked is $7.00, which implies a more modest 20.3% upside from recent levels. The high target is $7.50, and the most conservative is $6.00. In other words, the Maxim Group's $10 target is nearly 40% above the consensus median. This divergence highlights a clear split: one analyst sees the immediate catalysts as transformative, while the broader group remains cautious, perhaps factoring in the stock's elevated valuation and the inherent risks of a clinical-stage biotech.

From a technical perspective, the stock's position limits near-term downside. SLS is trading near the top of its 52-week range and above its 200-day moving average. This suggests the recent rally has built a strong floor, and a pullback from these levels would be a buying opportunity for momentum traders. The setup is now binary: the stock's technical strength and the Maxim Group's aggressive target create a clear path for further upside if the Phase 2 data delivers. However, the consensus view reminds us that such moves are not guaranteed, and the stock's valuation already prices in significant success.

The Competing Catalyst: GPS Phase 3 (REGAL) Readout

While the AML pipeline advances, a parallel, high-stakes event is building that could shift investor focus and capital allocation. The Phase 3 REGAL trial for Galinpepimut S (GPS) is progressing toward its topline readout, and recent data suggests a high probability of success. The trial's primary endpoint is median overall survival, and a predictive model based on the hard data from the trial points to a compelling result.

The model, built by a deep value investor with statistical expertise, analyzes the trial's event counts. As of December 26, 2025, the study had recorded 72 of the 80 required events across its 126 patients. The model predicts with 91% accuracy that the Best Available Therapy (BAT) median overall survival is 10-14 months. More specifically, it estimates a 99% accuracy that BAT median OS is 11.4 months. This is critical because the trial's success threshold is a hazard ratio of 0.636. A BAT median OS of 11.4 months, combined with the expected treatment effect, suggests the GPS arm could achieve a statistically significant improvement, potentially establishing the vaccine as a new standard of care for AML patients in second remission.

This creates a competing catalyst. The AML program has two near-term events: the AACR data presentation and the Phase 2 enrollment. The GPS Phase 3 readout represents a single, binary event that could validate a multi-year development program and unlock substantial value. For capital allocation, a positive REGAL result could draw investor attention and funding away from the earlier-stage AML initiatives, as it represents a more advanced, potentially transformative outcome. The setup is now a race between these two catalysts, each with the power to move the stock decisively.

Risk/Reward & What to Watch

The event-driven setup for SLS is now a clear binary choice. The immediate catalyst is the Phase 2 trial for SLS009, with topline data expected in the fourth quarter of 2026. The preclinical data presented last week is "compelling" but remains preclinical; it sets the stage but does not constitute proof of efficacy in patients. The real test is the Phase 2 readout, which will determine if the drug can deliver in its targeted high-unmet-need groups. Until that data arrives, the stock's momentum is driven by hope, not proof.

This creates a high-risk, high-reward profile. The stock has already surged 393.2% over the past year, meaning any disappointment in the Phase 2 results could trigger a sharp reversal. The setup is a classic biotech event: a late-stage drug advancing through a critical trial, with the market pricing in success. The recent 6% pop on the preclinical news shows how sensitive the stock is to catalysts, but it also highlights the valuation already baked in.

Against this, the GPS Phase 3 readout represents a more distant but potentially larger catalyst. While the AML program has two near-term events, the GPS trial is a single binary event that could validate a multi-year development effort. A positive result there could draw significant investor attention and capital, potentially overshadowing the AML pipeline until the Phase 2 data arrives.

The key near-term watchpoint is the Phase 2 topline data expected in Q4 2026. Until then, the stock will trade on sentiment around the AACR presentation and the trial's progress. For an event-driven strategist, the risk is clear: the stock's massive run-up leaves little room for error. The reward hinges entirely on the Phase 2 trial delivering.